| Not Yet Recruiting | Evaluation of the Quality of Life in Patients With Chronic Iron Overload Due to Hemoglobinopathies in Greece. NCT07352878 | Elpen Pharmaceutical Co. Inc. | — |
| Not Yet Recruiting | Impact of Iron Overload on the Incidence of Liver Complications in Long-Term Survivors (≥10 Years) of Allogene NCT07028112 | Assistance Publique - Hôpitaux de Paris | — |
| Recruiting | Neurodegenerative Diseases Progression Markers (MARKERS-NDD) NCT06596746 | Casa di Cura San Raffaele Cassino | — |
| Recruiting | Fully Automated High-Throughput Quantitative MRI of the Liver NCT05294471 | University of Wisconsin, Madison | — |
| Recruiting | Heme and Non-heme Iron Intakes, Gut Microbiota, and Influence on Host Iron Absorption NCT06146608 | Cornell University | — |
| Completed | Long-term Clinical Study of CN128 in Thalassemia With Sever Liver Iron Overloaded Patients NCT05355766 | Hangzhou Zede Pharma-Tech Co., Ltd. | Phase 2 |
| Completed | Inhibitory Effect of a Polyphenol Supplement on Dietary Iron Absorption in Adults with Thalassemia NCT05326503 | Swiss Federal Institute of Technology | N/A |
| Completed | MRI QSM Imaging for Iron Overload NCT04631718 | University of Wisconsin, Madison | — |
| Terminated | Safety of SP-420 in the Treatment of Transfusional Iron Overload NCT04741542 | The University of Texas Health Science Center at San Antonio | Phase 1 |
| Completed | Risk Factors and Measures to Prevent Liver and Pancreas Complications in Pediatric Patients After HSCT NCT04423237 | University of Pisa | — |
| Completed | Long-term Clinical Study of CN128 in Thalassemia Patients NCT04614779 | Hangzhou Zede Pharma-Tech Co., Ltd. | Phase 2 |
| Withdrawn | SP-420 in Subjects With Transfusion-dependent Beta-Thalassemia or Other Rare Anemias NCT03801889 | Abfero Pharmaceuticals, Inc | Phase 2 |
| Unknown | MRI T2* Mapping of Myocardium, Liver, Pancreas and Pituitary Gland NCT04835285 | Federal Research Institute of Pediatric Hematology, Oncology and Immunology | N/A |
| Completed | Hydroxy Urea, Omega 3, Nigella Sativa,Honey on Oxidative Stress and Iron Chelation in Pediatric Major Thalasse NCT04292314 | Beni-Suef University | Phase 2 / Phase 3 |
| Completed | Inhibiting Dietary Iron Absorption in Subjects With Hereditary Hemochromatosis by a Natural Polyphenol Supplem NCT03990181 | Swiss Federal Institute of Technology | N/A |
| Withdrawn | Validation of a Point-of-care Device Measuring Ferritin With Capillary Blood NCT03800446 | McMaster University | N/A |
| Active Not Recruiting | Ethnic Differences in Iron Absorption (FeGenes) NCT04198545 | Cornell University | — |
| Terminated | The Iron Content of Ferritin in Serum and Urine of Children With High Serum Ferritin Levels NCT03777904 | University of Utah | — |
| Completed | Safety and Efficacy of Early Treatment With Deferiprone in Infants and Young Children NCT03591575 | Chiesi Canada Corp | Phase 4 |
| Completed | Safety Study of Crushed Deferasirox Film Coated Tablets in Pediatric Patients With Transfusional Hemosiderosis NCT03372083 | Novartis Pharmaceuticals | Phase 4 |
| Completed | Iron Supplementation and Side Effects NCT04018300 | Iowa State University | N/A |
| Withdrawn | Comparing CGM and OGTT in Relation to Iron Overload Detected by Pancreas T2* MRI in High-Risk Hematology Group NCT03141398 | Hamad Medical Corporation | — |
| Completed | Endocrine Function During Deferasirox Therapy NCT04515680 | University of Campania Luigi Vanvitelli | — |
| Unknown | Study of MRI Monitoring in Patients With Aplastic Anemia and Low or Int-1 Risk of MDS Complicated With Iron Ov NCT02833493 | Peking Union Medical College Hospital | — |
| Completed | Confounder-Corrected Quantitative MRI Biomarker of Hepatic Iron Content NCT02025543 | University of Wisconsin, Madison | — |
| Unknown | Amlodipine as Adjuvant Treatment to Iron Chelation for Prevention of Cardiac Iron Overload in Thalassemia Pati NCT02474420 | Kevin H.M. Kuo, MD, MSc, FRCPC | N/A |
| Terminated | Long-term Safety and Efficacy of Ferriprox® in Iron Overloaded Patients With Sickle Cell Disease or Other Anem NCT02443545 | ApoPharma | Phase 4 |
| Completed | Non-invasive Quantification of Liver Iron With MRI NCT02425956 | GE Healthcare | N/A |
| Withdrawn | Treatment of Iron Overload Requiring Chelation Therapy NCT01927913 | Shire | Phase 2 |
| Terminated | Safety and Pharmacokinetic Study of Escalating Doses of SP-420, an Iron Chelator, in Patients With β-Thalassem NCT02274233 | Sideris Pharmaceuticals | Phase 1 |
| Terminated | Efficacy and Safety of Ferriprox® in Patients With Sickle Cell Disease or Other Anemias NCT02041299 | ApoPharma | Phase 4 |
| Completed | Iron Homoeostasis in Inflammation NCT02155114 | University Hospital, Basel, Switzerland | — |
| Completed | Evaluation of Myocardial Iron Deposition in Patients of Heart Failure Using T2* MR Imaging NCT02527330 | Chang Gung Memorial Hospital | — |
| Completed | Focal Accumulation of Iron in Cerebral Regions in Early ALS (Amyotrophic Lateral Sclerosis) Patients NCT02164253 | University Hospital, Lille | Phase 2 |
| Unknown | "Iron Overload and Endocrinological Diseases" NCT06137079 | Azienda Ospedaliero-Universitaria di Modena | — |
| Completed | Amlodipine in the Prevention and Treatment of Iron Overload in Patients With Thalassemia Major NCT01395199 | University of Campinas, Brazil | Phase 3 |
| Completed | Massive Iron Deposit Assessment NCT01572922 | St. Jude Children's Research Hospital | N/A |
| Completed | Non-invasive Quantification of Liver Iron With MRI NCT01516853 | University of Wisconsin, Madison | — |
| Unknown | Iron Metabolism in Small Pre Term Newborns NCT01443195 | HaEmek Medical Center, Israel | N/A |
| Completed | Safety and Efficacy of Desferasirox in Chinese Patients With Iron Overload and Aplastic Anemia NCT01546415 | Novartis Pharmaceuticals | Phase 4 |
| Terminated | Phlebotomy and Risk of Hepatocellular Carcinoma in Patients With Compensated Alcoholic Cirrhosis NCT01342705 | Assistance Publique - Hôpitaux de Paris | Phase 3 |
| Completed | Renal Function Among Thalassemia Patients Treated by a Oral Chelator Deferasirox NCT01905774 | HaEmek Medical Center, Israel | — |
| Completed | Oxidative Stress and Apoptosis of Energy Metabolism by Deferiprone From the Circulating Lymphocytes NCT02880033 | University Hospital, Lille | N/A |
| Completed | Effects of Phlebotomy on Insulin Sensitivity in Insulin Resistance-associated Hepatic Iron Overload Patients NCT01572818 | Rennes University Hospital | N/A |
| Terminated | Deferasirox for Treating Patients Who Have Undergone Allogeneic Stem Cell Transplant and Have Iron Overload NCT01159067 | City of Hope Medical Center | Phase 2 |
| Unknown | Fetal Parenchymatic Evaluation (Liver, Spleen) Using T2* Sequences NCT01121094 | Sheba Medical Center | — |
| Completed | Efficacy and Safety of Desferal Versus Osveral in Transfusional Iron Overload NCT01369719 | Hormozgan University of Medical Sciences | N/A |
| Unknown | Assessment of Iron Deposition in Major Organs of Hemodialysis Patients NCT01169961 | Wolfson Medical Center | — |
| Completed | Phlebotomy and Lifestyle and Diet Advices vs Lifestyle and Diet Advices Only in Patients With Dysmetabolic Liv NCT01045525 | Rennes University Hospital | Phase 3 |
| Completed | Iron Overload in Pediatric Oncology Patients NCT01034072 | Northwell Health | — |
| Unknown | Safety of Various Mode of Delivery of Iron Supplement on Iron Toxicity Markers in Preschool Children NCT00980421 | Annamalai University | Phase 3 |
| Unknown | Therapeutic Effects of Silymarin in Patients With B-thalassemia Major NCT00999349 | Isfahan University of Medical Sciences | Phase 2 / Phase 3 |
| Completed | Open-Label Single-Arm Pilot Study in Adult Allogeneic Hematopoietic Stem Cell Transplant Recipients With Trans NCT01335035 | Novartis Pharmaceuticals | Phase 4 |
| Completed | Changes in Pituitary Iron and Volume With Deferasirox NCT01376622 | Children's Hospital Los Angeles | — |
| Unknown | Ferrochelating Treatment in Patients Affected by Neurodegeneration With Brain Iron Accumulation (NBIA) NCT00907283 | Ente Ospedaliero Ospedali Galliera | Phase 2 |
| Completed | Effects of Taking Prenatal Vitamin-mineral Supplements During Lactation on Iron Status and Markers of Oxidatio NCT01047098 | University of California, Davis | N/A |
| Completed | Oral Nifedipine to Treat Iron Overload NCT00712738 | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | Phase 1 |
| Completed | Efficacy and Safety of Oral Deferasirox (20 mg/kg/d) in Pts 3 to 6 Months After Allogeneic Hematopoietic Cell NCT00654589 | Novartis Pharmaceuticals | Phase 4 |
| Completed | MRI Evaluation of Iron Overload in the Heart, Liver and Pancreas in Patients Receiving Multiple Blood Transfus NCT00629291 | Sheba Medical Center | — |
| Completed | Iron Overload Assesment in Sickle Cell Anemia and Sickle Cell Thalassemia NCT00512226 | HaEmek Medical Center, Israel | N/A |
| Completed | Combined Chelation Therapy in Patients With Transfusion Dependent Thalassemia and Iron Overload NCT00901199 | Elliott Vichinsky | Phase 2 |
| Terminated | Deferasirox in Treating Patients With Iron Overload After Undergoing a Donor Stem Cell Transplant NCT00602446 | Masonic Cancer Center, University of Minnesota | Phase 2 |
| Completed | Safety and Efficacy of Ferriprox™ (Deferiprone) Oral Solution in Iron Overloaded Pediatric Patients NCT00529152 | ApoPharma | Phase 3 |
| Completed | Safety and Efficacy of Iron Reduction by Phlebotomy NCT00689182 | Andrea Kew | Phase 2 |
| Completed | Iron Overload in Stem Cell Transplant Recipients NCT00806715 | Boston Children's Hospital | — |
| Completed | Quantification of Liver Iron Overload and Steatosis Using Magnetic Resonance Imaging NCT00401336 | Rennes University Hospital | N/A |
| Unknown | Study of the Effects of Muscular Activity on Iron Metabolism NCT00378469 | Rennes University Hospital | N/A |
| Completed | Safety and Efficacy of Deferasirox (ICL670) in Patients With Iron Overload Resulting From Hereditary Hemochrom NCT00395629 | Novartis Pharmaceuticals | Phase 1 / Phase 2 |
| Approved For Marketing | Compassionate Use of Deferiprone for Patients With Thalassemia and Iron-Induced Heart Disease NCT00293098 | Children's Hospital of Philadelphia | — |
| Completed | Cardiac T2* in Beta-thalassemia Patients on Deferasirox Treatment NCT00447694 | Novartis | Phase 2 |
| Completed | Study for the Treatment of Transfusional Iron Overload in Myelodysplastic Patients NCT00117507 | Novartis Pharmaceuticals | Phase 4 |
| Completed | Study of Deferasirox for Treatment of Transfusional Iron Overload in Myelodysplastic Patients NCT00110266 | Novartis Pharmaceuticals | Phase 2 |
| Completed | Extension Study of the Efficacy and Safety of Deferasirox Treatment in Beta-thalassemia Patients With Transfus NCT00171301 | Novartis Pharmaceuticals | Phase 4 |
| Completed | Study of Deferasirox Relative to Subcutaneous Deferoxamine in Sickle Cell Disease Patients NCT00110617 | Novartis Pharmaceuticals | Phase 2 |
| Completed | Cytochrome P450 2E1 and Iron Overload NCT00138684 | Rennes University Hospital | Phase 2 |
| Completed | Retrospective Evaluation of Adult and Pediatric Transfusion-dependent Patients Treated With Deferasirox Therap NCT01874405 | University of Campania Luigi Vanvitelli | — |
| Completed | Intensive Combined Chelation Therapy for Iron-Induced Cardiac Disease in Patients With Thalassemia Major NCT00800761 | Ospedale Microcitemico | Phase 4 |
| Completed | Thalassemia (Cooley's Anemia) Clinical Research Network (TCRN) NCT00000623 | Carelon Research | — |
| Completed | Hemochromatosis and Iron Overload Screening Study (HEIRS) NCT00005541 | National Heart, Lung, and Blood Institute (NHLBI) | — |
| Completed | Combination Iron Chelation Therapy NCT00004982 | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | Phase 1 |
| Completed | Iron Overload in African Americans NCT00001455 | Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) | — |
| Completed | Chelation Therapy of Iron Overload With Pyridoxal Isonicotinoyl Hydrazone NCT00000588 | Case Western Reserve University | Phase 2 |
| Completed | Evaluation of Subcutaneous Desferrioxamine as Treatment for Transfusional Hemochromatosis NCT00000595 | National Heart, Lung, and Blood Institute (NHLBI) | Phase 2 |